CD59抗体

+ +

•  

   

     Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);    

  
  

•  

   

     Immunofluorescence analysis of MCF-7 cells using CD59 mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor-555 phalloidin.    

  
  

•  

   

     Immunofluorescence analysis of Hela cells using CD59 mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor-555 phalloidin.    

  
  

•  

   

     Flow cytometric analysis of HeLa cells using CD59 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human bladder cancer tissues using CD59 mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human esophageal cancer tissues using CD59 mouse mAb with DAB staining.    

  
  

CD59 antibody background:

CD59. a glycosylphosphatidylinositol (GPI)-anchored membrane protein, is a key regulator of the complement system. It inhibits the formation of the membrane attack complex (MAC) by binding to complement proteins C8 and C9. thereby protecting host cells from unintended complement-mediated lysis. CD59 is widely expressed on various cell types, including erythrocytes, endothelial cells, and immune cells.

Antibodies targeting CD59 have emerged as valuable tools in research and clinical applications. In research, CD59 antibodies are used to study complement regulation, cell-surface expression, and GPI-anchor deficiencies, such as in paroxysmal nocturnal hemoglobinuria (PNH), a disease characterized by CD59 deficiency leading to erythrocyte destruction. These antibodies also help elucidate CD59's role in immune evasion mechanisms exploited by pathogens or cancer cells.

Clinically, CD59 antibodies have diagnostic utility. For example, flow cytometry with anti-CD59 antibodies aids in diagnosing PNH by detecting CD59-negative blood cells. Therapeutically, blocking CD59 with antibodies has been explored to enhance complement-dependent cytotoxicity (CDC) in cancer therapy, as cancer cells often overexpress CD59 to evade immune attack. Conversely, in autoimmune or inflammatory conditions, CD59-targeting antibodies might mitigate excessive complement activation.

Challenges include ensuring antibody specificity and addressing variable CD59 expression across tissues. Ongoing research aims to optimize CD59 antibody applications in both understanding disease mechanisms and developing targeted therapies.